Seminars in Radiation Oncology最新文献_第10页

The Many Faces of Muscle-Invasive Bladder Cancer: Histopathological and Molecular Characterization 肌肉侵袭性膀胱癌的多面体:组织病理学和分子表征

IF 3.5 3区医学

Seminars in Radiation Oncology Pub Date : 2023-01-01 DOI: 10.1016/j.semradonc.2022.10.001

Brian Mau , Burles Johnson , Donna E. Hansel , David J. McConkey

引用次数: 0

Seeing is Believing: State of the Art Imaging of Bladder Cancer 眼见为实:膀胱癌成像技术的最新进展

IF 3.5 3区医学

Seminars in Radiation Oncology Pub Date : 2023-01-01 DOI: 10.1016/j.semradonc.2022.10.002

Emanuele Messina , Martina Pecoraro , Martina Lucia Pisciotti , Francesco Del Giudice , Sara Lucciola , Marco Bicchetti , Ludovica Laschena , Michela Roberto , Ettore De Berardinis , Giorgio Franco , Valeria Panebianco

{"title":"Seeing is Believing: State of the Art Imaging of Bladder Cancer","authors":"Emanuele Messina , Martina Pecoraro , Martina Lucia Pisciotti , Francesco Del Giudice , Sara Lucciola , Marco Bicchetti , Ludovica Laschena , Michela Roberto , Ettore De Berardinis , Giorgio Franco , Valeria Panebianco","doi":"10.1016/j.semradonc.2022.10.002","DOIUrl":"10.1016/j.semradonc.2022.10.002","url":null,"abstract":"<div>Imaging plays an important role in bladder cancer (BCa) diagnostic work-up. Ultrasound achieves an intermediate sensitivity in detecting urinary tract alterations and is considered a suboptimal imaging technique in diagnosis of BCa. CT urography accurately detects BCa in patients presenting with hematuria Multiparametric MRI achieves a very high rate of BCa detection and helps with accurate staging of patients; however, this modality is still not widely supported by international guidelines. The main applications of MRI are local tumor staging and differentiation between non-muscle-invasive BCa and muscle-invasive BCa. These applications led to development of Vesical Imaging-Reporting and Data System (VI-RADS) scoring system. The VI-RADS scoring system was developed in the setting of post-resection of primary bladder tumor and instillation of intravesical Bacillus Calmette-Guerin therapy; however validation of this system in the post-treatment setting showed promising results. The high risk of BCa recurrence leads to its application in the assessment of response to therapy and for disease surveillance after treatment. MRI is rapidly becoming a leading imaging modality in BCa diagnostic workup, assessment of response to therapies and for longitudinal surveillance, and plays an important role in BCa surgical and radiation therapy treatment planning.</div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9189541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Myths About Bladder Preservation in Muscle-Invasive Bladder Cancer 肌肉浸润性膀胱癌中膀胱保存的误区

IF 3.5 3区医学

Seminars in Radiation Oncology Pub Date : 2023-01-01 DOI: 10.1016/j.semradonc.2022.10.007

Thiraviyam Elumalai , Nuradh Joseph , Ananya Choudhury

引用次数: 0

Bladder Cancer Radiation Oncology of the Future: Prognostic Modelling, Radiomics, and Treatment Planning With Artificial Intelligence 未来的膀胱癌放射肿瘤学:预后建模、放射组学和人工智能治疗计划

IF 3.5 3区医学

Seminars in Radiation Oncology Pub Date : 2023-01-01 DOI: 10.1016/j.semradonc.2022.10.009

Nicholas S. Moore MD , Alan McWilliam PhD , Sanjay Aneja MD

引用次数: 3

The Emerging Evidence Supporting Integration of Deep Regional Hyperthermia With Chemoradiation in Bladder Cancer 支持深度局部热疗与放化疗联合治疗膀胱癌的新证据

IF 3.5 3区医学

Seminars in Radiation Oncology Pub Date : 2023-01-01 DOI: 10.1016/j.semradonc.2022.10.011

Oliver J. Ott , Udo S. Gaipl , Allison Lamrani , Rainer Fietkau

引用次数: 1

The Legacy of RTOG/NRG Protocols in Shaping Current Bladder Preservation Therapy in North America RTOG/NRG协议在形成当前膀胱保留治疗中的遗产在北美

IF 3.5 3区医学

Seminars in Radiation Oncology Pub Date : 2023-01-01 DOI: 10.1016/j.semradonc.2022.10.004

Sophia C. Kamran MD, Jason A. Efstathiou MD, DPhil

{"title":"The Legacy of RTOG/NRG Protocols in Shaping Current Bladder Preservation Therapy in North America","authors":"Sophia C. Kamran MD, Jason A. Efstathiou MD, DPhil","doi":"10.1016/j.semradonc.2022.10.004","DOIUrl":"10.1016/j.semradonc.2022.10.004","url":null,"abstract":"<div>For muscle-invasive bladder cancer, the historical, gold standard treatment was radical cystectomy. However, the notion of organ preservation using trimodality therapy (TMT, consisting of maximal transurethral resection of bladder tumor followed by chemoradiation) has been established as a viable treatment alternative to complete removal of the bladder. Despite the lack of direct head-to-head randomized comparisons of TMT to radical cystectomy, the Radiation Therapy Oncology Group (RTOG)/NRG has spearheaded the use of radiation therapy as part of bladder preservation for years, with prospective data demonstrating similar long-term clinical outcomes to cystectomy series, particularly with contemporary treatment. We summarize these trials and discuss the evolution of bladder preservation throughout the decades, culminating in our current TMT protocols. We further discuss the future of organ-preservation therapy in MIBC, with continued improvement in radiation techniques, incorporation of novel therapies, and personalization of treatment to optimize benefit for bladder cancer patients.</div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9175432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Bladder Preservation for Muscle-Invasive Bladder Cancer With Variant Histology 组织学变异的肌肉浸润性膀胱癌的膀胱保存

IF 3.5 3区医学

Seminars in Radiation Oncology Pub Date : 2023-01-01 DOI: 10.1016/j.semradonc.2022.10.008

Andrew Brocklehurst , Mohini Varughese , Alison Birtle

{"title":"Bladder Preservation for Muscle-Invasive Bladder Cancer With Variant Histology","authors":"Andrew Brocklehurst , Mohini Varughese , Alison Birtle","doi":"10.1016/j.semradonc.2022.10.008","DOIUrl":"10.1016/j.semradonc.2022.10.008","url":null,"abstract":"<div>A growing body of evidence has shown bladder-preservation with chemo-radiotherapy achieves comparable survival to Radical Cystectomy (5-year OS 50%-70%) and superior quality of life outcomes for patients with muscle-invasive urothelial carcinoma of the bladder (UC). However, up to 55% of patients harbor variant histology and in this review we aim to clarify the role of bladder-preservation for this group. We first draw the distinction between urothelial carcinoma with divergent differentiation (UCDD) and non-urothelial carcinoma (NUC). UCDD is common, increasing in prevalence, and whilst each subtype may have its own characteristics current evidence suggests comparable outcomes with radical cystectomy and bladder-preservation.Non-urothelial carcinoma is a collection of distinct pathologies each deserving of its own management strategy. However, these tumors are rare, and evidence is generated from retrospective studies with significant inherent bias. Small cell carcinoma of the bladder has good evidence for bladder-preservation; however, other pathologies such as Squamous Cell Carcinoma and Adenocarcinoma are not well supported. We recommend careful multidisciplinary appraisal of the evidence for each subtype and honest patient discussion about the limited evidence before reaching management decisions. As we look to the future molecular-profiling may help better characterize these tumors and aid in treatment selection.</div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9175436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Multidisciplinary Management and Radiotherapy Recommendations for Clinically and Pathologically Node-positive Bladder Cancer 临床和病理淋巴结阳性膀胱癌的多学科管理和放疗建议

IF 3.5 3区医学

Seminars in Radiation Oncology Pub Date : 2023-01-01 DOI: 10.1016/j.semradonc.2022.10.005

BhanuPrasad Venkatesulu , Stanley L. Liauw , Monika Joshi , Brian C. Baumann , Ryan Yoo , Morgan Roupret , Ananya Choudhury , Jason A. Efstathiou , Vedang Murthy , Paul Sargos , Abhishek A. Solanki

{"title":"Multidisciplinary Management and Radiotherapy Recommendations for Clinically and Pathologically Node-positive Bladder Cancer","authors":"BhanuPrasad Venkatesulu , Stanley L. Liauw , Monika Joshi , Brian C. Baumann , Ryan Yoo , Morgan Roupret , Ananya Choudhury , Jason A. Efstathiou , Vedang Murthy , Paul Sargos , Abhishek A. Solanki","doi":"10.1016/j.semradonc.2022.10.005","DOIUrl":"10.1016/j.semradonc.2022.10.005","url":null,"abstract":"<div>There are limited data regarding the optimal management of patients with pelvic node-positive, but non-metastatic, bladder cancer. Increasing data demonstrate that this is a distinct clinical entity with outcomes bridging between bladder-confined muscle-invasive bladder cancer and metastatic advanced bladder cancer. Guidelines and staging systems have formalized the need to incorporate the unique considerations of management of pelvic node-positive bladder cancer. However, there remains an absence of a definite standard of care. Treatment options include systemic therapy alone, neoadjuvant chemotherapy followed by radical cystectomy, or bladder-preserving trimodality therapy. Furthermore, ongoing studies aim to determine the benefit of incorporating immunotherapy into these treatment paradigms. In this review article, we will discuss the key considerations for management of patients with pelvic node-positive bladder cancer.</div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9189542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial Intelligence for Radiation Oncology Applications Using Public Datasets 使用公共数据集的放射肿瘤学应用人工智能

IF 3.5 3区医学

Seminars in Radiation Oncology Pub Date : 2022-10-01 DOI: 10.1016/j.semradonc.2022.06.009

Kareem A. Wahid , Enrico Glerean , Jaakko Sahlsten , Joel Jaskari , Kimmo Kaski , Mohamed A. Naser , Renjie He , Abdallah S.R. Mohamed , Clifton D. Fuller

{"title":"Artificial Intelligence for Radiation Oncology Applications Using Public Datasets","authors":"Kareem A. Wahid , Enrico Glerean , Jaakko Sahlsten , Joel Jaskari , Kimmo Kaski , Mohamed A. Naser , Renjie He , Abdallah S.R. Mohamed , Clifton D. Fuller","doi":"10.1016/j.semradonc.2022.06.009","DOIUrl":"10.1016/j.semradonc.2022.06.009","url":null,"abstract":"<div>Artificial intelligence (AI) has exceptional potential to positively impact the field of radiation oncology. However, large curated datasets - often involving imaging data and corresponding annotations - are required to develop radiation oncology AI models. Importantly, the recent establishment of Findable, Accessible, Interoperable, Reusable (FAIR) principles for scientific data management have enabled an increasing number of radiation oncology related datasets to be disseminated through data repositories, thereby acting as a rich source of data for AI model building. This manuscript reviews the current and future state of radiation oncology data dissemination, with a particular emphasis on published imaging datasets, AI data challenges, and associated infrastructure. Moreover, we provide historical context of FAIR data dissemination protocols, difficulties in the current distribution of radiation oncology data, and recommendations regarding data dissemination for eventual utilization in AI models. Through FAIR principles and standardized approaches to data dissemination, radiation oncology AI research has nothing to lose and everything to gain.</div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9265678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Artificial Intelligence and Deep Learning for Brachytherapy 近距离放射治疗的人工智能和深度学习

IF 3.5 3区医学

Seminars in Radiation Oncology Pub Date : 2022-10-01 DOI: 10.1016/j.semradonc.2022.06.008

Xun Jia , Kevin Albuquerque

引用次数: 0